bioRxiv Science⌕ Search

Biology subjects

Chugh, P.

Publications and source records attributed to Chugh, P..

2 recordsLinked to original sources

Transcriptional control of neuronal maintenance by SOX2 during inner ear innervation

The cochlear sensory epithelium and the spiral ganglion neurons it supports arise from a common pool of otic progenitors, yet the neurons remain dependent on the epithelium for guidance and survival long after the two lineages diverge. How that dependency is sustained as the progenitor pool generates increasingly restricted cell types is unknown. Here we show that SOX2 maintains this regulatory continuity. Deletion of Sox2 from the cochlear epithelium after cochlear neurogenesis does not affect neuroblast generation, delamination and proliferation; however, peripheral axons failed to reach the epithelium and neurons were progressively lost, identifying a non-cell-autonomous requirement for epithelial SOX2. Transcriptomic profiling revealed a SOX2-dependent epithelial programme enriched for neurotrophic and axon-guidance genes, including Ntf3 and Bdnf. In cochlear organoids, acute Sox2 deletion reduced H3K27ac at regulatory elements while H3K4me1 remained stable, consistent with SOX2 maintaining the activity of previously marked enhancers. Ntf3 and Bdnf exemplified distinct regulatory trajectories. At Ntf3, SOX2 occupied an enhancer whose activity depended on Sox2, whereas at Bdnf it occupied promoter-proximal elements in progenitors before ATOH1 engaged these and a hair-cell-active distal enhancer. Thus, SOX2 links sensory fate specification to epithelial-neuronal communication. More generally, our findings suggest that regulatory competence can persist through lineage restriction, while changing transcription-factor inputs partition its output among descendants to coordinate their development.

developmental biology↗

Circulating Biomarkers for Therapeutic Response to Immune Checkpoint Inhibitor Therapy in Patients with Advanced Lung Cancer

Immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in the treatment of advanced lung cancer (ALC), but not all patients benefit. To identify responders, patient selection, categorization, and the identification of specific predictive biomarkers are crucial. Our research aims to identify circulating metabolites that could be used to stratify patients into potential responders prior to the initiation of ICIs and to monitor clinical response in real-time during treatment. In the discovery phase, plasma samples (n = 25) from ALC patients receiving ICIs were analyzed using unbiased metabolomics and validated in a distinct patient cohort (n = 39). Five potential biomarkers were identified (FC > 1.5, p 0.05, AUC 0.81-1), including Thiourea and a combined metabolite panel (CMP) consisting of sphingosine-1-phosphate, gentisic acid, glutathione, and 4-hydroxybutanone. Early on-treatment high plasma levels of Thiourea were significantly associated with 5-year progression-free survival [Hazard ratio (HR) = 0.038, 95% confidence interval (CI) = 0.013-0.107, p<0.001] and overall survival [HR = 0.048, 95% CI = 0.019-0.120, p<0.001]. Low levels of CMP early on treatment were significantly associated with progression-free survival [HR = 8.119, 95% CI: 3.767-17.501, p<0.001] and overall survival [HR = 7.367, 95% CI: 3.517-15.433, 3.517-15.433, p<0.001]. This predictive plasma metabolite panel could serve as promising circulating biomarkers for predicting the therapeutic response of ICIs in ALC patients.

cancer biology↗